Update shared on 27 Nov 2025
Fair value Decreased 6.29%Analysts have lowered their price target for PROCEPT BioRobotics from $55.60 to $52.10 per share, citing a mix of cautious company guidance and continued anticipation of healthy revenue growth, even with recent market volatility.
Analyst Commentary
Recent analyst reports reflect a mix of optimistic outlooks and measured caution for PROCEPT BioRobotics, as price targets have been adjusted downward in the context of ongoing market volatility and evolving company guidance.
Bullish Takeaways
- Bullish analysts maintain Buy ratings on the stock, which indicates continued conviction in the company's long-term growth potential despite the recent target reductions.
- Revenue growth is still expected to be "healthy" for the upcoming quarter. This suggests underlying business momentum and resilient demand within the MedTech sector.
- Some view the company’s guidance as conservative. This implies there may be potential for PROCEPT BioRobotics to outperform the more cautious outlook presented by management.
- There is a belief that recent negative reactions in the stock price may be exaggerated. Some see the possibility of a positive re-rating as volatility subsides and fundamentals improve.
Bearish Takeaways
- Reduced price targets reflect a more tempered outlook on valuation, as expectations are recalibrated in response to current guidance and market conditions.
- Analysts are mindful of persistent stock volatility, particularly since flows from new investors remain limited across the sector.
- Specialist and fund positioning is seen as a potential driver of outsized market moves on any deviation from consensus expectations. This highlights execution risk.
- The sector remains sensitive to controversies and headline risk. Analysts are more comfortable with companies that offer clearer paths to sustained growth.
What's in the News
- PROCEPT BioRobotics reiterated earnings guidance for 2025 and maintained its full-year revenue projection at approximately $325.5 million. This represents a 45% increase compared to the previous year (Key Developments).
- The company provided revenue guidance for 2026, projecting revenue between $410 million and $430 million. This would reflect year-over-year growth of 26% to 32% over the 2025 guidance range (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from $55.60 to $52.10 per share, reflecting a modest downward revision.
- Discount Rate has risen slightly from 7.80% to approximately 7.80%.
- Revenue Growth projections have dipped slightly, moving from 25.64% to 25.62% year-over-year growth expectations.
- Net Profit Margin is projected to improve, increasing from 13.09% to 13.38%.
- Future P/E (Price-to-Earnings ratio) has fallen significantly, dropping from 60.8x to 48.4x. This may indicate more conservative forward earnings expectations or valuation adjustments.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.